Accueil VisioCyt EN

Accroche

VisioCyt® allows an earlier diagnosis of bladder cancer from a simple urine sample. 

This innovative solution is based on a patented technology combining fluorescence imaging and artificial intelligence. 

VisioCyt® obtained the CE mark in January 2020.

Technology
Infographie
Image
infographic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image de fond
Image
banner
Clinical
Texte

The VisioCyt® 1 clinical trial started in January 2017. This trial was conducted in collboration with 14 French hospitals and included 1360 patients.

The goal is to evaluate the diagnostic perfomances of VisioCyt® in the event of a bladder tumor suspicion.

 

Image
clinique
About us
Texte

VitaDX has developed an innovative solution for the early diagnosis of bladder cancer, based on a patented technology combining image processing and artificial intelligence. VitaDX leverages research work, carried out by researchers from the Institut des Sciences Moléculaires d'Orsay (ISMO, UMR CNRS and Université Paris-Sud) and practitioners from the Kremlin Bicêtre hospital (AP-HP) whose goal was to diagnose bladder cancer earlier to optimise patient care.

 

Image
VitaDx
News
Dernières actualités
VitaDX
4th round of financing for VitaDX
21 September 2020 - News

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

Image de fond
Image
banner
Contact
Nom commercial
VisioCyt / VitaDX International
Numéro de téléphone
(+33)143214455
74F, rue de Paris
35000 Rennes, France
28 rue de Chambéry
75015 Paris, France
Formulaire
Image CAPTCHA
Enter the characters shown in the image.